IQVIA Holdings Inc. announced its financial results for the second quarter of 2025, reporting revenue of $4,017 million, a 5.3% increase year-over-year. The company achieved a GAAP net income of $266 million, with diluted earnings per share of $1.54. The Technology & Analytics Solutions segment saw revenue growth of 8.9%, while the Research & Development Solutions segment reported a 2.5% increase. The company also noted a contracted backlog of $32.1 billion, which is expected to contribute approximately $8.1 billion in revenue over the next twelve months.
In the first half of 2025, IQVIA's total revenue reached $7,846 million, up 3.9% compared to the same period in 2024. The company repurchased $607 million of its common stock during the second quarter, bringing the total for the year to over $1 billion. As of June 30, 2025, IQVIA had cash and cash equivalents of $2,039 million and total debt of $15,490 million, resulting in a net debt of $13,451 million. The company has updated its full-year revenue guidance to between $16,100 million and $16,300 million.
linkJul 22, 2025 07:06:22
The company has submitted its financial statements and exhibits as required by the Securities Exchange Act of 1934. This filing was signed by Eric M. Sherbet on June 4, 2025.
linkJun 04, 2025 16:30:40
IQVIA Holdings Inc. announced that its subsidiary, IQVIA Inc., intends to raise $2 billion through an offering of senior notes due in 2032. The proceeds from this offering will primarily be used to repay existing borrowings under its revolving credit facility, as well as cover fees and expenses associated with the offering. Any remaining funds will be allocated for general corporate purposes.
The offering is subject to market and customary conditions and will not be available to the general public. The notes have not been registered under the Securities Act and are being offered only to qualified institutional buyers in the United States and non-U.S. investors outside the United States. The company emphasizes that this announcement does not constitute an offer or solicitation for the sale of the notes.
linkJun 02, 2025 17:22:00
IQVIA Holdings Inc. announced its financial results for the first quarter of 2025, reporting revenue of $3,829 million, a 2.5 percent increase compared to the same period last year. The company achieved a GAAP net income of $249 million and adjusted EBITDA of $883 million. R&D Solutions experienced a contracted backlog of $31.5 billion, reflecting a year-over-year growth of 4.8 percent. Additionally, the Technology & Analytics Solutions segment reported revenue growth of 6.4 percent on a reported basis, while the company’s operating cash flow was $568 million, and free cash flow reached $426 million, up 13 percent year-over-year. The company also repurchased $425 million of its common stock during the quarter.
IQVIA has raised its full-year 2025 revenue guidance by $275 million, now estimating revenue between $16,000 million and $16,400 million, due to favorable foreign currency exchange rates. The profit guidance, including adjusted EBITDA between $3,765 million and $3,885 million, remains unchanged. The company reaffirmed its adjusted diluted earnings per share guidance, which is projected to be between $11.70 and $12.10. As of March 31, 2025, IQVIA's cash and cash equivalents were $1,740 million, with total debt of $14,330 million, resulting in a net debt of $12,590 million.
linkMay 06, 2025 07:04:26
The company has fulfilled its obligations under the Securities Exchange Act of 1934, ensuring that the necessary documentation has been signed by authorized representatives. This compliance reflects the company's commitment to regulatory standards and transparency in its financial reporting.
No specific financial metrics or performance indicators were disclosed in this press release, and there are no notable negative points mentioned. The focus remains solely on the compliance aspect of the filing.
linkMar 10, 2025 16:30:40
IQVIA Holdings Inc. reported a fourth-quarter revenue of $3,958 million, which is a 2.3 percent increase compared to the same quarter last year. The company also achieved a GAAP net income of $437 million, although this represents a 6.8 percent decline year-over-year. Adjusted earnings metrics showed positive growth, with Adjusted Net Income rising 7.8 percent to $564 million and Adjusted Diluted Earnings per Share increasing by 9.9 percent to $3.12. The company also noted a significant increase in free cash flow, which grew by 41 percent year-over-year to reach $2,114 million for the full year of 2024. Additionally, R&D Solutions reported a strong contracted backlog of $31.1 billion, reflecting a 5.5 percent year-over-year growth at constant currency.
On the downside, the company faced challenges in its Research & Development Solutions, where revenue decreased by 1.3 percent on a reported basis. The Contract Sales & Medical Solutions segment also saw a revenue decline of 4.8 percent. Although the overall revenue for the full year increased by 2.8 percent, the GAAP net income growth was modest at just 1.1 percent year-over-year. Furthermore, the company’s GAAP diluted earnings per share saw a slight increase of 2.7 percent, indicating that while some aspects of financial performance improved, others faced headwinds.
linkFeb 06, 2025 07:04:44
IQVIA Holdings Inc. reported a revenue of $3,896 million for the third quarter of 2024, reflecting a 4.3 percent increase compared to the same period last year. The company's Technology & Analytics Solutions (TAS) revenue grew by 8.6 percent to $1,554 million, while the Research & Development Solutions (R&DS) revenue saw a smaller increase of 1.9 percent. The GAAP net income was $285 million, and the adjusted diluted earnings per share rose to $2.84, marking a 14.1 percent increase year-over-year. Additionally, the company reported a significant increase in operating cash flow and free cash flow, both up over 30 percent year-over-year. The contracted backlog for R&DS grew to $31.1 billion, an 8.0 percent increase from the previous year, indicating a solid pipeline for future revenue generation.
On the downside, the report highlighted a decline in Contract Sales & Medical Solutions (CSMS) revenue, which fell by 1.6 percent to $180 million. The book-to-bill ratio of 1.06x was impacted by a large program cancellation due to drug futility, although it was reported at 1.22x when excluding this cancellation. Furthermore, the company updated its full-year 2024 revenue guidance to reflect delays in two major trials, which are now expected to ramp up in the second half of 2025. This adjustment in guidance could potentially affect investor sentiment as it indicates challenges in meeting previously anticipated growth targets.
linkOct 31, 2024 07:05:10
IQVIA's Q2 2024 results show revenue growth, with GAAP net income of $363 million and adjusted EBITDA of $887 million. The company's R&D Solutions segment saw positive performance, with a $30.6 billion contracted backlog, representing a 7.7% growth year-over-year. Full-year 2024 revenue guidance was updated positively. CEO Ari Bousbib highlighted strong operational execution and growth in adjusted diluted EPS.
linkJul 22, 2024 07:05:57
IQVIA's Q1 2024 results show revenue growth, strong bookings, and a healthy backlog, with adjusted EBITDA up 1.3%. The company reaffirms its full-year revenue guidance and expects growth in Adjusted EBITDA and Diluted EPS. Cash flow remains robust, with net debt at $12,092 million. IQVIA continues to focus on providing analytics, technology solutions, and clinical research services to the life sciences industry, aiming to accelerate medical advancements and improve healthcare outcomes.
linkMay 02, 2024 08:41:54
IQVIA reported a 3.5% increase in revenue for Q4 2023, with strong performance in Technology & Analytics and Research & Development Solutions. The company's contracted backlog grew by 9.2% year-over-year, and it expects a significant portion to convert to revenue in the next twelve months. Despite a decrease in Adjusted Net Income, the company's GAAP Net Income and Diluted Earnings per Share showed significant year-over-year growth. IQVIA also provided positive guidance for 2024, expecting revenue between $15,400 million and $15,650 million, with a positive outlook for Adjusted EBITDA and Adjusted Diluted Earnings per Share.
linkFeb 14, 2024 07:05:19